Meghan Adrienne Dureen

Meghan Dureen practices exclusively in the area of intellectual property law with a focus on proceedings under the Patented Medicines (Notice of Compliance) Regulations . Dr. Dureen completed her J.D. at the University of Toronto. Prior to law school, Dr. Dureen received a Bachelor of Science in Chemistry from the University of British Columbia and a Ph.D. in Chemistry from the University of Toronto. Her research has been published in scientific journals including the Journal of the American Chemical Society, Inorganic Chemistry and Organometallics.

Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding apalutamide.

Action under section 8.2 of the Patented Medicines (Notice of Compliance) Regulations regarding apalutamide.

Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding aflibercept.

Action under section 8.2 of the Patented Medicines (Notice of Compliance) Regulations regarding aflibercept.

Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,832,157 (brexpiprazole).